<DOC>
	<DOCNO>NCT00199160</DOCNO>
	<brief_summary>This Phase II trial evaluate efficacy biological activity BAY 43-9006 patient recurrent and/or metastatic head neck cancer .</brief_summary>
	<brief_title>Efficacy Activity BAY 43-9006 Patients With Recurrent and/or Metastatic Head Neck Cancer</brief_title>
	<detailed_description>This Phase II trial evaluate efficacy biological activity BAY 43-9006 patient recurrent and/or metastatic head neck cancer .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Male female patient ( 18 year old ) , histologically proven , measurable , locally recurrent , and/or metastatic head neck tumor . &gt; 4 week since major surgery &gt; 4 week since prior chemotherapy &gt; 3 week since prior therapy biological agent ( Interleukin2 [ IL2 ] , interferon , moleculartargeted therapy [ except Ras/Raf inhibitor ] ) . Performance status &lt; 2 Life expectancy &gt; 3 month . At least one unidimensional measurable lesion compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) accord Response Evaluation Criteria Solid Tumors ( RECIST ) Adequate liver , pancreatic , renal , coagulation function A slide paraffinblock tumor biopsy MUST available time screen . If original diagnostic biopsy available time screening , additional biopsy require . Severe preexist condition Evidence bone marrow suppression Frequent vomit medical condition , could interfere oral medication intake Lack resolution toxic manifestation prior chemotherapy , biologic , radiation therapy ( alopecia exclude ) . Known HIV positivity AIDSrelated illness . Previous exposure Ras/Raf inhibitor Previous malignancy ( except cervical carcinoma situ , adequately treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis T1 ] malignancy curatively treat &gt; 2 year prior entry ) Congestive heart failure Cardiac arrhythmia require antiarrhythmic Active coronary artery disease ischaemia Active clinically serious bacterial fungal infection Known brain meningeal metastases Patients seizure disorder require medication ( antiepileptic ) Substance abuse , medical , psychological , social condition may interfere patient 's participation study evaluation study result Known suspect allergy investigational agent agent give association trial Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test . Concurrent anticancer chemotherapy immunotherapy exclude Significant surgery within four week prior start study drug Investigational drug therapy outside trial , chemotherapy within 4 week prior start study drug Myelosuppressive radiotherapy within four week prior start study drug ( shortcourse nonmyelosuppressive radiotherapy may allow base approval principal investigator ) Concomitant treatment ketoconazole , itraconazole , ritonavir , use grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>local recurrence metastatic disease</keyword>
	<keyword>Previously treat platinum</keyword>
	<keyword>carcinoma head neck</keyword>
</DOC>